Posted on 1/24/19
Ohr Pharmaceutical Announces Reverse Stock Split
NEW YORK, Jan. 23, 2019 (GLOBE NEWSWIRE) -- Ohr Pharmaceutical, Inc. (Nasdaq: OHRP) announced today that its board of directors has determined to effect a one-for-twenty . . .
Posted on 1/23/19
PTC Therapeutics Announces Pricing of Public Offering of Common Stock
PTC Therapeutics, Inc. (Nasdaq: PTCT) announced today the pricing of a public offering of 6,720,000 shares of its common stock at a public offering price of . . .
Posted on 1/23/19
Bellerophon Prices $7M Public Offering
WARREN, N.J., Jan. 23, 2019 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH), a clinical-stage biotherapeutics company, today announced the pricing of an underwritten public offering . . .
Posted on 1/23/19
Pfizer Looks To Move Tafamidis Forward With Priority Review
SummaryPfizer announced that it had submitted both NDA applications to receive FDA approval for tafamidis to treat patients with transthyretin amyloid cardiomyopathy.The priority review designation was . . .
Posted on 1/23/19
Johnson & Johnson (JNJ) Q4 2018 Earnings Conference Call Transcript
IMAGE SOURCE: THE MOTLEY FOOL.Johnson & Johnson (NYSE:JNJ) Q4 2018 Earnings Conference CallJan. 22, 2019 8:30 a.m. ETContents:Prepared RemarksQuestions and AnswersCall ParticipantsPrepared Remarks:OperatorGood morning. Welcome to . . .
Posted on 1/23/19
Pfizer: Still A Cash Cow
SummaryOperational cash flows continue to increase.They continue to cover financing and investing activities.Remaining long.This idea was discussed in more depth with members of my private investing . . .
Posted on 1/23/19
Better Buy: Pfizer vs. AbbVie
If you've been looking for big pharma stocks with juicy dividend yields, you've probably noticed Pfizer (NYSE:PFE), and AbbVie (NYSE:ABBV) recently. AbbVie currently offers a better . . .
Posted on 1/23/19
Slowing Growth Worries Johnson & Johnson Shareholders
The healthcare sector drew a lot of attention from investors in 2018, and as one of the industry's leaders, Johnson & Johnson (NYSE:JNJ) has often been . . .
Posted on 1/23/19
PTC Therapeutics Proposes Public Offering of Common Stock
PTC Therapeutics, Inc. (Nasdaq: PTCT) announced today that it is commencing a public offering of $200 million of shares of its common stock. All of the . . .
Posted on 1/23/19
UroGen Pharma Proposes Public Offering of Ordinary Shares
NEW YORK--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq:URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in the field of urology, with a focus on uro-oncology, . . .
Posted on 1/23/19
Bellerophon Therapeutics Proposes Public Offering of Common Stock
WARREN, N.J., Jan. 22, 2019 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH), a clinical-stage biotherapeutics company, today announced that it intends to offer and sell, . . .
Posted on 1/22/19
Johnson & Johnson Reports 2018 Fourth-Quarter Results
Johnson & Johnson (NYSE: JNJ) today announced sales of $20.4 billion for the fourth quarter of 2018, an increase of 1.0% as compared to the fourth . . .
Posted on 1/22/19
Bristol-Myers/Celgene: The Spread Is Your Friend
Summary There is a pending 16 percent spread between the current price of Celgene and the take-out price. Investors are concerned about the viability of the . . .
Posted on 1/22/19
Would Pfizer Shareholders Win With an Acquisition of Amarin?
January historically brings deals and rumors of deals in the biopharmaceutical industry. The first few weeks in 2019 haven't disappointed, with a couple of big buyouts . . .
Posted on 1/22/19
Better Buy: AbbVie vs. Johnson & Johnson
AbbVie (NYSE:ABBV) and Johnson & Johnson (NYSE:JNJ) partner on one of the hottest cancer drugs on the market, Imbruvica. But the two big drugmakers are rivals . . .
Posted on 1/22/19
Xybion Partners with Northwell Health
LAWRENCEVILLE, N.J.--(BUSINESS WIRE)--Xybion Corporation announced today it is partnering with Northwell Health to strengthen workforce safety at its hospitals and outpatient facilities. New York State’s largest . . .
Posted on 1/18/19
Children's Hospital Colorado And University of Colorado Partner With CareDox
Children's Hospital Colorado, the University of Colorado School of Medicine at CU Anschutz Medical Campus, and CareDox today announced a new collaboration to scale the reach . . .
Posted on 1/18/19
Cooper University Health Care First Hospital Site in the Nation
Camden, NJ, Jan. 18, 2019 (GLOBE NEWSWIRE) -- Cooper University Health Care recently entered into an agreement with the United States Army to provide advanced surgical . . .
Posted on 1/18/19
Celgene: Great Opportunities For Option Investors
SummaryTo me, special situations give investors the opportunity to enhance their total return.With little downside risk potential and annualized returns of more than 30%, Celgene shares . . .
Posted on 1/18/19
Why Bristol-Myers Squibb Stock Sank By 15.2% in 2018
What happened Biopharma heavyweight Bristol-Myers Squibb (NYSE:BMY) saw its shares sink by a staggering 15.2% in 2018, according to data from S&P Global Market Intelligence. What . . .
Posted on 1/18/19
Parker Awards a $2.5M Grant to VNA Health Group
Parker Foundation, Inc. has awarded a $2.5M grant to Visiting Nurse Association Health Group (VNA) to support its Advanced Care Institute (ACI), which aims to address . . .
Posted on 1/17/19
Amarin: Evaluating The Merits Of A Potential Pfizer Acquisition
SummaryVascepa is approved as a treatment for hypertriglyceridemia. Despite a slow initial ramp up, sales of Vascepa is increasing drastically.Amarin recently posted the stellar data for . . .
Posted on 1/17/19
Is Pfizer a Buy?
It's been a long time since Pfizer (NYSE:PFE) shareholders have seen any revenue growth. Product sales peaked in 2010, but the company now has what it . . .
Posted on 1/16/19
Bristol-Myers Squibb Stock Issued For Celgene: I Plan To Keep It
Summary The Bristol-Myers Squibb acquisition undervalues Celgene. Bristol-Myers would also be undervalued post-deal at current prices. I am inclined to keep the BMY stock I receive. . . .
Posted on 1/16/19
Taro Completes $250 Million Share Repurchase Program
HAWTHORNE, N.Y.--(BUSINESS WIRE)--Taro Pharmaceutical Industries Ltd. (NYSE: TARO) announced today that it has completed its $250 million share repurchase program. The company bought back 2,493,378 of . . .

